{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:48:48Z","timestamp":1762868928102,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Atypical hemolytic uremic syndrome (aHUS), also called complement-mediated hemolytic uremic syndrome (CM-HUS), is a rare disease caused by dysregulation in the alternative complement activation pathway. It is a life-threatening condition causing ischemia of a number of organs, and it typically causes acute kidney injury. This disorder may be triggered by various factors including viral or bacterial infections, pregnancy, surgery, and injuries. In about 60% of cases, the genetic origin of the disease can be identified\u2014commonly mutations affecting complementary factor H and MCP protein. Eculizumab, a monoclonal antibody to the C5 component of the complement, represents the current effective treatment.We describe a case of a young woman with a previous history of polyvalent allergies, who developed atypical hemolytic uremic syndrome after vaccination with mRNA vaccine against SARS-CoV-2. The disease manifested by scleral bleeding, acute renal insufficiency, anemia, and thrombocytopenia. The patient was treated with <jats:italic>plasma exchanges<\/jats:italic> without sufficient effect; remission occurred only after starting treatment with eculizumab. Genetic examination showed that the patient is a carrier of multiple inherited risk factors (a rare pathogenic variant in <jats:italic>CFH<\/jats:italic>, MCPggaac haplotype of the <jats:italic>CD46<\/jats:italic> gene, and the risk haplotype <jats:italic>CFH<\/jats:italic> H3). The patient is currently in hematological remission with persistent mild renal insufficiency, continuing treatment with eculizumab\/ravulizumab. By this case report, we meant to point out the need for careful monitoring of people after vaccination, as it may trigger immune-mediated diseases, especially in those with predisposing factors.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1001366","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T09:36:06Z","timestamp":1664357766000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Romana","family":"Rysava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Peiskerova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Tesar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Benes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kment","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"Szil\u00e1gyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorottya","family":"Csuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Proh\u00e1szka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: Conclusions from a kidney disease: Improving global outcomes (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04674.x","article-title":"Complement activation in thrombotic thrombocytopenic purpura","volume":"10","author":"R\u00e9ti","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(88)90160-3","article-title":"An ELISA technique for the measurement of C1q in cerebrospinal fluid","volume":"114","author":"Delamarche","year":"1988","journal-title":"J Immunol Methods"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.molimm.2016.01.003","article-title":"Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome","volume":"71","author":"Szarvas","year":"2016","journal-title":"Mol Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2005.030783","article-title":"The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor h and membrane cofactor protein: Evidence from two independent cohorts","volume":"42","author":"Fremeaux-Bacchi","year":"2005","journal-title":"J Med Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: A\u00a0nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0147-7","article-title":"Eculizumab: A review of its use in atypical haemolytic uraemic syndrome","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Eng J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-016-0288-3","article-title":"Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment","volume":"30","author":"Van de Walle","year":"2017","journal-title":"J Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.796109","article-title":"Complement levels at admission reflecting progression to severe acute kidney injury (AKI) in coronavirus disease 2019 (COVID-19): A multicenter prospective cohort study","volume":"9","author":"Henry","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.07.004","article-title":"Atypical hemolytic and uremic syndrome triggered by infection with SARS-CoV2","volume":"6","author":"Kaufeld","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.030","article-title":"Atypical HUS relapse triggered by COVID-19","volume":"99","author":"Ville","year":"2021","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.017","article-title":"ANCA glomerulonephritis after the moderna COVID-19 vaccination","volume":"100","author":"Sekar","year":"2021","journal-title":"Kidney Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.016","article-title":"De novo vasculitis after mRNA-1273 (Moderna) vaccination","volume":"100","author":"Anderegg","year":"2021","journal-title":"Kidney Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.07.026","article-title":"A case of ANCA-associated vasculitis after AZD1222 (Oxford\u2013AstraZeneca) SARS-CoV-2 vaccination: Casualty or causality","volume":"100","author":"Villa","year":"2021","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.07.016","article-title":"A case of membranous nephropathy following pfizer-BioNTech mRNA vaccination against COVID-19","volume":"100","author":"Da","year":"2021","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.001","article-title":"Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination","volume":"100","author":"Aydin","year":"2021","journal-title":"Kidney Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.07.019","article-title":"Relapse of class V lupus nephritis after vaccination with COVID-19 mRNA vaccine","volume":"100","author":"Tuschem","year":"2021","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.07.020","article-title":"Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination","volume":"100","author":"Plasse","year":"2021","journal-title":"Kidney Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.07.018","article-title":"Scleroderma renal crisis following mRNA vaccination against SARS-CoV-2","volume":"100","author":"Oniszczuk","year":"2021","journal-title":"Kidney Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000519461","article-title":"Atypical hemolytic uremic syndrome after ChAdOx1 nCoV-19 vaccination in a patient with homozygous CFHR3\/CFHR1 gene deletion","volume":"146","author":"Ferrer","year":"2022","journal-title":"Nephron"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012152","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: What we know and do not know","volume":"138","author":"Arepally","year":"2021","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.789972","article-title":"Case report: A case of COVID vaccine-induced thrombotic thrombocytopenia manifested as pulmonary embolism and hemorrhagia","volume":"4","author":"Ihnatko","year":"2022","journal-title":"A First Reported Case From Slovakia Front Med (Lausanne)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011958","article-title":"Prothrombotic immune thrombocytopenia after COVID-19 vaccine","volume":"138","author":"Tiede","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1001366\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T12:47:40Z","timestamp":1664974060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1001366\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2022.1001366"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1001366","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"article-number":"1001366"}}